PBS boost for melanoma patients
1 March 2020
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
All resected Stage III patients, regardless of BRAF mutation, now have subsidised access to nivolumab as adjuvant (after surgery) treatment. This is the first adjuvant immunotherapy for resected Stage III patients to be listed on the PBS, and follows clinical trials showing the therapy’s effectiveness in preventing the disease from progressing to Stage IV and spreading throughout the body.
Importantly, today’s PBS listing also includes immunotherapy as first line treatment for high risk and advanced melanoma patients who are BRAF positive. Previously, these patients were required to first undergo treatment with BRAF inhibitors and were only eligible for subsidised immunotherapy after their melanoma progressed or recurred.
Making this treatment accessible and affordable as first-line therapy for these patients will significantly increase their chances of response and long-term survival.
Today’s announcement is welcome news and a wonderful way to begin MIA's month-long awareness and fundraising campaign, Melanoma March.
‘MIA patients and their families lobbied hard for these PBS listings for many months, and this outcome is a credit to their dedication,’ said MIA Co-Medical Director Professor Richard Scolyer.
‘We thank everyone who submitted comments for consideration by the Federal Government’s PBAC, as these submissions, along with the tireless work from our team of researchers, clinicians and colleagues around the country, have now secured affordable access to these life-saving treatments for melanoma patients,’ added Co-Medical Director Professor Georgina Long.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.